Novo Nordisk (NVO)
(Delayed Data from NYSE)
$126.95 USD
+1.51 (1.20%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $127.00 +0.05 (0.04%) 5:22 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Balance Sheet
Fiscal Year End for Novo Nordisk AS falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4,730 | 3,724 | 3,051 | 1,954 | 2,348 |
Receivables | 10,928 | 8,143 | 7,446 | 4,931 | 4,370 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4,619 | 3,453 | 3,122 | 2,840 | 2,644 |
Other Current Assets | 0 | 0 | 0 | 357 | 0 |
Total Current Assets | 20,277 | 15,320 | 13,618 | 10,082 | 9,362 |
Net Property & Equipment | 13,208 | 9,441 | 8,808 | 7,701 | 7,578 |
Investments & Advances | 241 | 190 | 229 | 252 | 271 |
Other Non-Current Assets | 208 | 29 | 42 | 103 | 126 |
Deferred Charges | 2,959 | 1,901 | 1,380 | 899 | 618 |
Intangibles | 8,771 | 7,281 | 6,869 | 3,165 | 875 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 45,663 | 34,162 | 30,946 | 22,202 | 18,829 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3,718 | 2,207 | 1,411 | 876 | 953 |
Current Portion Long-Term Debt | 941 | 208 | 2,177 | 1,143 | 221 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 1,033 | 1,004 | 582 | 599 | 631 |
Other Current Liabilities | 18,942 | 13,706 | 11,663 | 8,148 | 7,036 |
Total Current Liabilities | 24,634 | 17,125 | 15,833 | 10,766 | 8,842 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1,476 | 1,000 | 839 | 383 | 12 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 2,981 | 3,443 | 2,062 | 444 | 451 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1,101 | 772 | 957 | 908 | 891 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 30,191 | 22,340 | 19,691 | 12,501 | 10,196 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 65 | 65 | 74 | 72 | 72 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | 15,223 | 11,411 | 11,456 | 9,770 | 8,667 |
Other Equity | 185 | 347 | -273 | -140 | -104 |
Treasury Stock | 1 | 1 | 1 | 1 | 2 |
Total Shareholder's Equity | 15,473 | 11,822 | 11,256 | 9,701 | 8,633 |
Total Liabilities & Shareholder's Equity | 45,663 | 34,162 | 30,946 | 22,202 | 18,829 |
Total Common Equity | 15,473 | 11,822 | 11,256 | 9,701 | 8,633 |
Shares Outstanding | 4,487.50 | 4,525.90 | 4,709.60 | 4,709.60 | 4,736.00 |
Book Value Per Share | 3.45 | 2.61 | 2.39 | 2.06 | 1.82 |
Fiscal Year End for Novo Nordisk AS falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 9,041 | 1,612 | 4,730 | 7,402 | 5,699 |
Receivables | 10,986 | 10,447 | 10,928 | 9,047 | 10,303 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5,246 | 4,892 | 4,619 | 4,312 | 4,094 |
Other Current Assets | 341 | 0 | 0 | 0 | 0 |
Total Current Assets | 25,613 | 16,951 | 20,277 | 20,761 | 20,096 |
Net Property & Equipment | 15,870 | 14,302 | 13,208 | 11,893 | 10,961 |
Investments & Advances | 239 | 240 | 241 | 215 | 216 |
Other Non-Current Assets | 314 | 293 | 208 | 63 | 49 |
Deferred Charges | 3,256 | 3,053 | 2,959 | 2,747 | 2,281 |
Intangibles | 8,009 | 8,684 | 8,771 | 8,136 | 7,414 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 53,302 | 43,523 | 45,663 | 43,815 | 41,018 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4,294 | 1,894 | 3,718 | 2,935 | 2,599 |
Current Portion Long-Term Debt | 787 | 1,480 | 941 | 966 | 919 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 852 | 868 | 1,033 | 1,795 | 1,405 |
Other Current Liabilities | 21,182 | 19,870 | 18,942 | 19,496 | 17,959 |
Total Current Liabilities | 27,115 | 24,112 | 24,634 | 25,193 | 22,882 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1,304 | 1,407 | 1,476 | 1,151 | 1,114 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 7,447 | 2,441 | 2,981 | 2,909 | 2,837 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1,199 | 1,101 | 985 | 967 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 37,065 | 29,121 | 30,191 | 30,238 | 27,800 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 64 | 66 | 65 | 66 | 66 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | 16,183 | 14,422 | 15,223 | 13,393 | 12,874 |
Other Equity | -11 | -85 | 185 | 118 | 279 |
Treasury Stock | 0 | 1 | 1 | 1 | 0 |
Total Shareholder's Equity | 16,237 | 14,401 | 15,473 | 13,577 | 13,218 |
Total Liabilities & Shareholder's Equity | 53,302 | 43,523 | 45,663 | 43,815 | 41,018 |
Total Common Equity | 16,237 | 14,401 | 15,473 | 13,577 | 13,218 |
Shares Outstanding | 4,487.50 | 4,487.50 | 4,487.50 | 4,487.50 | 4,487.50 |
Book Value Per Share | 3.62 | 3.21 | 3.45 | 3.03 | 2.95 |